We will conduct a double-blind, randomized, placebo-controlled trial to evaluate the erythropoietin mouthwash effect on oral mucositis (OM) incidence and severity in 80 patients with hematological malignancies, undergoing autologous hematopoietic SCT (HSCT).A total of 80 adult patients with NHL, hodgkin disease (HD) or multiple myeloma (MM), undergoing autologous HSCT, are neededto enroll in the study. Major inclusion criteria are age of at least 18 years old, patients with NHL, HD or MM receiving conditioning chemotherapy before autologousHSCT and signing written informed consent. Major exclusion criteria areKarnofsky performance status <70% or participation in another study using an unlicensed product.Patients will receive either erythropoietin mouthwash (50 IU/mL, 15 ml four times a day) (n = 40) or placebo (n = 40) from the starting day of high dose chemotherapy until day +14 after transplantation.OM incidence, severity and duration will be evaluated as primary study outcomes using five-grade World Health Organization (WHO) oral toxicity scale. Several indices will be assessed as secondary outcomes including the duration of ANC under 500 cells/mm3, neutrophil and platelet engraftment time, the incidence and duration of fever and length of hospital stay.